A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)

Novartis300 enrolled

Overview

This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

Hypertension

Interventions

SPP100DRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed as essential hypertension - Exclusion Criteria: * Patients with secondary hypertension or suspected of having secondary hypertension. * Patients suspected of having malignant hypertension * Patients with any serious diseases or symptoms

Locations (1)

Novartis Pharmaceuticals

Basel, Switzerland

Outcomes

Primary Outcomes

Incidence of adverse events, vital signs, abnormal laboratory changes,etc.

Secondary Outcomes

Change from baseline in diastolic blood pressure after 52 weeks

Change from baseline in systolic blood pressure after 52 weeks

Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.